NISPA

Nijmegen Institute for Scientist-Practitioners in Addiction

Baclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study.

TitelBaclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study.
PublicatietypeJournal Article
Jaar van publicatie2015
AuteursKamal RM, Schellekens A, DeJong CA, Dijkstra BAG
UitgaveBMC Psychiatry
Volume15
Pagina's91
Publicatiedatum2015
ISSN1471-244X
Samenvatting

BACKGROUND: GHB dependence is a growing health problem in several western countries, especially the Netherlands. Attempts to stop using GHB are often followed by relapse shortly after successful detoxification. Craving for GHB use and co-morbid psychiatric symptom levels are thought to be the major factors contributing to the high relapse rates. Given its pharmacological profile, baclofen might prove an effective anti-craving agent for patients with GHB dependence. The aim of the current study is to assess the potential of baclofen as an anti-craving agent relapse prevention intervention in GHB dependent patients.

METHODS/DESIGN: In an open label non-randomized trial treatment with baclofen to a maximum of 60 mg/day will be compared with treatment as usual (TAU) in recently detoxified GHB dependent patients (n = 80). The primary outcome measure will be the level of GHB use. Secondary outcome measures are craving levels, psychiatric symptom levels and quality of life. Questionnaires will be administered during 12 weeks of baclofen treatment and at follow-up (six months after the start of treatment).

DISCUSSION: It is hypothesized that baclofen treatment compared to TAU will be associated with significantly reduced GHB use. In addition, we hypothesize that baclofen treatment will be associated with decreased craving and anxiety levels, and higher quality of life. If results are in line with our hypotheses, further studies on the efficacy of baclofen using placebo controlled designs and long term follow-up are warranted.

TRIAL REGISTRATION: The Netherlands Trial Register with number NTR4528 . Registered 19 April 2014.

DOI10.1186/s12888-015-0471-4
Alternatieve uitgaveBMC Psychiatry
PubMed ID25927622
PubMed Central IDPMC4424532